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Abstract 47 
Background 48 
To date, numerous nucleic acid species have been detected in the systemic circulation 49 
including microRNAs (miRNAs); however their functional role in this compartment 50 
remains unclear.  51 
Objective 52 
The aim of this study was to determine whether systemic levels of miRNAs abundant in 53 
blood, including the neuroendocrine tissue-enriched miR-375, are altered in response to a 54 
glucose challenge.  55 
Design 56 
Twelve healthy males were recruited for an acute cross-over study which consisted of 57 
two tests each following an eight-hour fasting period. An oral glucose tolerance test 58 
(OGTT) was performed and blood samples were collected over a 3-hour period. 59 
Following a period of at least one week, the same participants were administered an 60 
isoglycemic intravenous glucose infusion (IIGI) with the same blood collection protocol.  61 
Results 62 
The glucose response curve following the IIGI mimicked that obtained after the OGTT, 63 
but as expected systemic insulin levels were lower during the IIGI compared to the 64 
OGTT (P<0.05). MiR-375 levels in circulation were increased only in response to an 65 
OGTT and not during an IIGI. In addition, the response to the OGTT also coincided with 66 
the transient increase of circulating glucagon-like peptide-1 (GLP-1), glucagon-like 67 
peptide-2 (GLP-2), and glucose-dependent insulinotropic polypeptide (GIP). 68 
Conclusions 69 
The present findings show levels of miR-375 increase following administration of an 70 
OGTT and in light of its enrichment in cells of the gut, suggest that the gastrointestinal 71 
tract may play a significant role to the abundance and function of this microRNA in the 72 
blood. 73 
 74 
Précis 75 
Here we show using a clinical cohort the impact of glucose administered orally on miR-76 
375 in the blood. This result suggests a role for the gut in regulating miR-375 levels in 77 
systemic circulation. 78 
 79 
Abbreviations: 80 
IIGI  Isoglycemic intravenous glucose infusion 81 
GLP-1  Glucagon-like peptide-1 82 
GLP-2  Glucagon-like peptide-2 83 
GIP  Glucose-dependent insulinotropic polypeptide 84 
miRNA microRNA 85 
OGTT  Oral glucose tolerance test 86 
 87 
 88 
 89 
 90 
 91 
 92 
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Introduction 93 
It is now widely accepted that miRNAs are present in the circulation; however their 94 
precise function in this compartment is not completely understood (1)(2)(3). MiR-375 is 95 
an abundant miRNA that has been identified in several tissues including pancreatic islets, 96 
the pituitary, adrenal glands, and the gastrointestinal tract (4). Whereas miR-375 has been 97 
established as a regulator of pancreatic -cell function, its expression profile beyond this 98 
one cell type suggests a prominent role in other metabolic processes (5)(6)(7). Previous 99 
reports have identified miR-375 in the blood indicating that endocrine cells may 100 
contribute to its presence in circulation (1). As studies also now show alterations in 101 
systemic levels of miRNAs during disease states, it is still unclear how the kinetics of the 102 
miRNAs in circulation reflect changes in metabolism and physiology (8). Whether the 103 
miRNAs are actively released in response to changes in systemic glucose or other factors 104 
present in blood or whether they are constitutively released has also not been described. 105 
In response to dietary intake, several hormones including insulin and the incretins, 106 
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide 107 
(GIP), are released into the blood to facilitate several physiological processes and 108 
ultimately to lower blood glucose levels by promoting insulin release (9). GLP-1 is 109 
released by the intestinal endocrine L-cells and performs an array of functions in addition 110 
to its direct action on the -cell. GLP-1 acts to slow gastric emptying while indirectly 111 
inhibiting glucagon secretion via the release of somatostatin. Meanwhile, GIP present in 112 
the K-cells of the small intestine, will facilitate energy storage via direct action on 113 
adipose tissue, and promote bone formation by increasing osteoblast proliferation (9). 114 
Studies primarily in rodent models have begun to explore the role of GLP-1 and GIP in 115 
other tissues including the brain and together these observations highlight the complex 116 
nature of incretin action in the context of energy homeostasis. 117 
In this study we sought to determine whether miRNAs are released into the 118 
systemic circulation following a glucose challenge in human subjects and whether the 119 
presence of specific miRNAs coincide with established factors regulating glucose 120 
homeostasis. To date, extensive miRNA profiling has been performed on human tissues 121 
including blood. Here we show the systemic level of miR-375 is increased following oral 122 
ingestion of glucose implicating a role for the gut in the release of this small RNA into 123 
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circulation. We also observe that miR-375 is the most highly abundant and enriched 124 
miRNA in Sox9-High cells of the intestine, and robustly expressed and enriched in Sox9-125 
Low cells, suggesting that the enteroendocrine cell population, and possibly the 126 
proliferating cells of the intestinal crypt, may contribute to systemic levels of this 127 
miRNA. 128 
 129 
Materials and Methods 130 
Human Patient Samples 131 
As previously reported, approval was obtained from the Danish Data Protection Agency 132 
(2007-58-0010) and the Ethics Committee of the Central Denmark Region (1-16-02-377-133 
13) and informed consent was obtained from all patients for being included in the study 134 
(10). Twelve healthy Caucasian males, aged 20 to 50 years, participated in the study 135 
which was registered at ClinicalTrials.gov (NCT02213276). During the OGTT and IGII 136 
experiments, blood samples were collected at 0, 15, 30, 60, 120, and 180 minutes from 137 
receiving the glucose load which lasted 5 minutes. For the 3-hour fasting control 138 
experiment, blood samples were collected after 0, 1, 2 and 3 hours. Blood samples for 139 
plasma analysis of insulin, GIP, GLP-1 and GLP-2 were prepared and quantified at the 140 
Department of Clinical Biochemistry at Aarhus University Hospital accredited in 141 
accordance with ISO15189 (10). After collection, blood samples were centrifuged at 142 
2000 x g for 10 minutes and then stored at -80°C until analysis. Plasma insulin was 143 
measured by ELISA (cat. no. K6219; Dako, Glostrup, Denmark). All samples were 144 
extracted in a final concentration of 70% ethanol before GIP and GLP-1 measurements 145 
and 75% before GLP-2 measurements. Total GIP was measured using a 146 
radioimmunoassay with a C-terminally directed antibody (antiserum. no. 80867), which 147 
reacts fully with intact GIP and N-terminally truncated forms (11). The standard was 148 
human GIP (Bachem, cat no. H-5645) and the tracer was 125I-labeled human GIP (Perkin 149 
Elmer, cat no. Nex402). Total GLP-1 was measured using a radioimmunoassay with an 150 
antibody (antiserum. no. 89390) specific for the C-terminal of the GLP-1 molecule and 151 
reacting equally with intact GLP-1 and the primary (N-terminally truncated) metabolite 152 
(12). Intact GLP-2 was measured using a radioimmunoassay as originally described (13). 153 
The antiserum (code no. 92160) is directed against the N-terminus of GLP-2 and 154 
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therefore measures only fully processed GLP-2 of intestinal origin. For standards, we 155 
used recombinant human GLP-2 and the tracer was 125I-labeled rat GLP-2 with an Asp33 156 
-> Tyr33 substitution. Sensitivity for all the radioimmunoassays was below 5 pmol/l, and 157 
intra-assay coefficient of variation below 10 %. 158 
Gene Expression Analysis 159 
Total RNA was isolated from plasma using Trizol LS (Invitrogen) with glycogen as a 160 
carrier. MiRNAs were quantified by TaqMan Assays using the TaqMan MicroRNA 161 
Reverse Transcription Kit and miRNA specific primer sets (Thermo Scientific). Plasma 162 
miR-375, miR-148a, and miR-27b levels were normalized to miR-16 expression in each 163 
respective sample.  164 
Small RNA Sequencing Analysis 165 
Raw miRNA counts were retrieved from Supplementary Table 4 of Kang et al. 2017 (14). 166 
The publically available data was downloaded from Sequence Read Archive FTP site and 167 
NCBI dbGaP on 12/08/2015 resulting in 823 data sets from human tissue samples from 168 
and 395 data sets originating from serum and CSF. The precise details of the analysis can 169 
be retrieved from the Material and Methods section of Kang et al. 2017 (14). 170 
Tissue samples were normalized to estimated number of miRNA molecules per 171 
cell and we assumed the total amount of miRNA per cell to be ~100,000 (15). Counts for 172 
individual miRNA were divided by the sum of all miRNA reads in the sample and 173 
multiplied with the assumed total miRNA abundance. The same normalization was 174 
applied to body fluid samples but as the total abundance of miRNA in those fluids is 175 
unknown, the values do not represent copies per cell and are indicated as 'arbitrary units'. 176 
In total, 1787 miRNA were detected and analyzed; independent sample sizes were blood 177 
cells (n=197), liver cells (n=93), brain cells (n=102), serum samples (n=212), exosome 178 
samples (n=37) and cerebrospinal fluid (CSF) (n=180). In summary, the number of times 179 
a given miRNA is detected in sequencing depends on its abundance and the overall 180 
sequencing depth (16).  181 
 For small RNA sequencing from gut tissue of Sox9-EGFP mice, IEC isolation 182 
and FACS was performed with the UNC Flow Cytometry Core Facility as described 183 
previously (17). RNA was isolated from sorted subpopulations using the Total RNA 184 
Purification Kit (Norgen Biotek), and small RNA libraries were prepared with a range of 185 
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~60ng to ~850ng of total RNA using the CleanTag Small RNA Ligation Kit (TriLink 186 
Biotechnologies, CA) at the sequencing facility at the University of Texas Health 187 
Sciences Center, San Antonio. Libraries were sequenced on the Illumina HiSeq2500 188 
platform, yielding an average of ~40 million total reads per sample. Raw sequencing data 189 
and miRNA quantification tables for all samples can be accessed through the NCBI GEO 190 
accession number GSE XXXX. 191 
Animal Studies. 192 
All animal studies were approved by the Institutional Animal Care and Use Committee at 193 
the University of North Carolina, where the mouse experiments were performed. Chow-194 
fed male Sox9-EGFP mice were housed in cages with ¼-inch Bed-O’cobs laboratory 195 
animal bedding. At 24-28 weeks of age, the mice were anesthetized using isofluorane, 196 
then euthanized by cervical dislocation.  197 
Statistical analysis 198 
Comparisons between data sets with two groups were evaluated using an unpaired 199 
Student’s t-test. Repeated measures ANOVA was performed using GraphPad Prism 200 
Software 6.07 to compare levels of miR-375, glucose, insulin and gastrointestinal 201 
hormones between OGTT, IIGI and the 3-hour fasting control (Supplemental Table 1). 202 
Post hoc statistics were performed using Sidak’s multiple comparison test. A P-value of 203 
less than or equal to 0.05 was considered statistically significant.  204 
 205 
Results 206 
Quantification of miR-375 in human blood 207 
Surveying miRNA abundances in >800 human samples from six different tissues and 208 
body fluids we observed high abundances of miR-16 in all analyzed tissues including 209 
blood cells, liver, brain, serum, exosome and CSF samples (Figure 1a and 1b). In 210 
contrast, miR-375 was only abundant in serum, exosomes, liver and CSF, while it was 211 
moderately expressed in the brain and virtually absent in blood cells. This lack of 212 
expression in blood cells suggests that miR-375 may be exported into the bloodstream by 213 
adjoining tissues. In contrast, miR-124 was found to be only moderately expressed in the 214 
brain and was at low levels in all other analyzed tissues (Figure 1b). This further 215 
underlines the differential tissue expression pattern and function of miRNAs. 216 
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Systemic miR-375 increases during OGTT  217 
In light of its abundance in circulation, we quantified systemic miR-375 levels in 218 
the plasma of healthy human subjects in response to either an OGTT or an isoglycemic 219 
IIGI. Blood glucose levels were comparable between the OGTT and IIGI experiments 220 
(Figure 2a). The plasma miR-375 level significantly increased during the OGTT where it 221 
reached a maximum after 60 and 120 min (~4.8 and ~5.3-fold increase, respectively) and 222 
returned to baseline level after 180 min. In contrast, during the IIGI expression of this 223 
microRNA remained indistinguishable from steady state levels (Figure 2a, Supplemental 224 
Figure 1a, and Supplemental Table 1).  225 
The oral glucose administration resulted in a pronounced increase in circulating 226 
gut hormones GIP, GLP-1, GLP-2 (at time 30 minutes, ~3.9, ~2.2, and ~3.5-fold 227 
increase, respectively) as well as plasma insulin (~8.5-fold) as recently published (Figure 228 
2b-f) (10). During the intravenous glucose infusion plasma levels of GIP, GLP-1 and 229 
GLP-2 remained at baseline levels, while insulin showed only a small increase (Figure 230 
2c-f). Together these results indicate the temporal rise in miR-375 correlates with 231 
increased levels of the gut hormones and this is further supported with both area-under-232 
curve calculations and analyzing miR-375 levels using analysis of covariance 233 
(ANCOVA), as plotted in relation to GIP or GLP-1 (Supplemental Figure 1b-e). 234 
Meanwhile, we also addressed the expression of two additional miRNAs abundant in 235 
human serum, miR-148a amd 27b, and observed no changes in systemic levels during the 236 
OGTT or IIGI (Suppementary Figure 2a and 2b) (14).  237 
MiR-375 is enriched in enteroendocrine cells 238 
We next performed small RNA-sequencing on intestinal epithelial subpopulations 239 
isolated from 24-28-week-old male Sox9-EGFP reporter mice to identify cell types 240 
enriched for miR-375 (Figure 3) (18)(19). As described previously, FACS sorting 241 
resulted in four independent cell populations: the Sox9-High group is enriched for 242 
enteroendocrine cells and reserve/quiscent intestinal stem cells (Figure 3a), Sox9-Low is 243 
enriched for actively-cycling intestinal stem cells (Figure 3b), Sox9-Sublow is enriched 244 
for transit amplifying cells (Figure 3c), and Sox9-Neg is enriched for enterocytes (Figure 245 
3d) (17). Together, these results show that miR-375 is the most highly expressed and 246 
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highly enriched miRNA in Sox9-High cells and is also robustly expressed and enriched 247 
in Sox9-Low cells (though not as high as in Sox9-High cells). 248 
 249 
Discussion 250 
Our knowledge is incomplete with regards to the dynamics and function of the majority 251 
of circulating factors in human blood. It has long been known that administration of 252 
glucose orally versus intravenously differentially affects the release of insulin due to the 253 
role of the incretins in islet cell function; however the full extent to the interplay of these 254 
endocrine factors in the context of glucose and energy metabolism remains to be 255 
determined (20)(21). In the present study, we observed the presence of miRNA sequences 256 
known to be enriched in tissues central to the regulation of glucose and energy 257 
homeostasis including miR-375. Interestingly, higher levels of miR-375 were observed in 258 
the plasma of human subjects following an oral glucose challenge in contrast to an 259 
intravenous glucose infusion. Levels of miR-375 peaked 30 minutes after the peaks of 260 
insulin and incretins, establishing that systemic increase of miR-375 is temporally 261 
associated the release of these hormones. The differential response of miR-375 in blood 262 
may yet identify an additional physiologic function of the gut or its secreted incretin 263 
hormones. Consistent with previous observations, both methods of glucose 264 
administration achieved similar blood glucose levels while the insulin secretory response 265 
was diminished during the IIGI (22)(23). The robust increase in plasma insulin levels 266 
quantified during the OGTT coincided with a concomitant increase in plasma GLP-1, 267 
GLP-2, and GIP. Hence, these results present correlative evidence that the gut may play 268 
either a direct or indirect role in the regulation of the circulating levels of miR-375 in 269 
response to oral glucose.  270 
It is also unclear whether our results are related to previous studies measuring 271 
miR-375 in blood after pharmacological destruction of beta cell mass; previous studies 272 
have reported an alteration in the cellular distribution within the gastrointestinal tract 273 
after administration of streptozotocin to mice (24)(25)(26). Latreille et al. reported that 274 
the pancreatic -cell, the cell type expressing the highest levels of miR-375, contributes 275 
to ~1% of the systemic miR-375 levels, indicating that the amount of miRNAs released 276 
by the -cell is either negligible in comparison to other tissues or they are rapidly taken 277 
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up or they are degraded once in circulation (25). It is also possible that several endocrine 278 
cell types release miR-375 in response to incretin signaling in line with their role as 279 
paracrine effectors and insulin secretagogues. 280 
 Our observations here showing a rise in miR-375 levels in blood following the 281 
oral intake of glucose suggests several possibilities regarding the role of the gut with 282 
regard to the presence miRNAs in circulation. First, circulating levels of this miRNA 283 
may either originate from the gut or respond to signaling molecules released by this 284 
tissue. Our profiling results from sorted cells of the gut confirm miR-375 to be highly 285 
abundant in subpopulations enriched for both enteroendocrine cells and intestinal stem 286 
cells (and also present albeit at lower levels in transit-amplifying cells and enterocytes) 287 
(27). In light of the heterogeneity of L-cells, another possibility is that L-cells of the 288 
upper gut act primarily in nutrient sensing while in the lower gut, these cells contribute to 289 
the release of miR-375 (28). The highest levels of miR-375 were measured between 30 290 
and 120 minutes post-administration; therefore the presence of this miRNA in the 291 
secretory granules storing either insulin or GLP-1 is unlikely. It is unclear how many 292 
additional miRNAs the differential impact of oral glucose versus intravenous on systemic 293 
levels will be shown to affect as abundant sequences such as miR-148a and miR-27b 294 
were observed not altered. 295 
A recent study by Kahn and colleagues has shown evidence that circulating 296 
miRNAs are derived from adipose tissue and are able to target genes of the liver (29). 297 
Using a tissue-specific knockout of the miRNA-processing enzyme Dicer, they observed 298 
a decrease in circulating miRNAs present in exosomes and that over-expression of miR-299 
99b was able to suppress activity of a reporter construct containing the 3’UTR of the 300 
gene Fgf21, a circulating factor expressed by the liver and other tissues (29). MiR-375 is 301 
also detected in liver and while expression of miR-375 in this tissue is several magnitudes 302 
lower than the levels measured in the pancreatic islet, miR-122 is detected in blood 303 
suggesting the hepatocyte is also a site of miRNA export (6)(30)(31). However, it would 304 
be prudent for future investigations to determine whether the measured amounts of miR-305 
375 are endogenous expression from hepatocytes. Given the volume of blood transported 306 
throughout the liver, it is likely a significant fraction of miR-375 expression quantified in 307 
this tissue is derived from its presence in the systemic circulation. Therefore the 308 
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functional relevance of miR-375 in the liver at steady state conditions is unclear at this 309 
time. Given the dozens of other more abundant miRNA sequences present, most notably 310 
miR-122, the function of low-expressed miRNAs is not known based on the absence of 311 
strong evidence showing target regulation in vivo. While dysregulation of miR-375 target 312 
genes in the liver cannot be ruled out, none of the targets of this miRNA that were 313 
experimentally-validated using knockout tissues, have been studied in the context of 314 
glucose or lipid metabolism in the liver (4). The mild hyperglycemia observed in miR-315 
375 knockout mice appears to result from increased glucagon levels stemming from 316 
increased alpha cell mass in the islet (4). 317 
 In summary, our observations on miR-375 in circulation continue to reflect the 318 
exceedingly complex and dynamic state of human blood following glucose uptake. In 319 
light of the temporal relationship between miR-375 and incretin hormones, future studies 320 
should explore the physiological relevance of miRNA in circulation and whether 321 
functional overlap exists between non-coding RNA and signaling hormones.  322 
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 455 
Figure Legends 456 
Figure 1. Abundances of miR-375, miR-16 and miR-124 in three human tissues and 457 
three body fluids. (a) Abundances of the three miRNAs in blood cells, liver and brain. 458 
The vertical axis shows estimated miRNA molecules per cell, logarithmic scale. (b) 459 
Abundances in serum, exosome and cerebrospinal fluid. The vertical axis indicates 460 
arbitrary units for cell-free samples. In total, 197 blood cell, 93 liver, 102 brain, 212 461 
serum, 37 exosome and 180 cerebrospinal samples were profiled. 462 
 463 
Figure 2. Measurements of miR-375, glucose, insulin, GIP, GLP-1, and GLP-2 in the 464 
plasma of healthy human individuals during an oral glucose tolerance test (OGTT), 465 
intravenous isoglycemic glucose infusion (IIGI), and a 3-hour fasting control (open 466 
circles (OGTT), filled squares (IIGI), and open squares (control)). (a) Plasma miR-375 467 
levels during the OGTT (open circles), the IIGI (filled squares), and during the control 468 
(open squares). (b) Plasma glucose concentrations during the OGTT (open circles), the 469 
IIGI (filled squares), and during the control (open squares). (c) Plasma insulin 470 
concentrations during the OGTT (open circles), the IIGI (filled squares), and during the 471 
control (open squares). (d) Plasma GIP concentrations during the OGTT (open circles), 472 
the IIGI (filled squares) ), and during the control (open squares). (e) Plasma GLP-1 473 
concentrations during the OGTT (open circle), the IIGI (filled squares), and during the 474 
control (open squares). (f) Plasma GLP-2 concentrations during the OGTT (open circle), 475 
the IIGI (filled squares), and during the control (open squares). Results are presented as 476 
mean ± SEM. Data on plasma glucose, insulin, GLP-1, GLP-2, and GIP have recently 477 
been published and are reproduced with permission (10). The summary of statistical 478 
analyses for these datasets is compiled in Supplemental Table 1. 479 
 480 
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Figure 3. MiR-375 is highly expressed and significantly enriched in independent 481 
intestinal epithelial subpopulations. (a) Bar graph showing normalized levels of 482 
expression for miR-375 (y-axis) from small RNA-sequencing across four different 483 
intestinal epithelial subpopulations (x-axis) in 24-week-old male Sox9-EGFP reporter 484 
mice (n=3). Sox9-High (enriched for enteroendocrine cells), Sox9-Low (enriched for 485 
intestinal stem cells), Sox9-Sublow (enriched for transit-amplifying cells), and Sox9-Neg 486 
(enriched for enterocytes). RPMMM, reads per million mapped to microRNAs. (b) 487 
Scatter plot showing average expression of microRNAs from small RNA-sequencing in 488 
Sox9-High cells (y-axis) and fold-enrichment in Sox9-High cells relative to unsorted 489 
intestinal epithelial cells (x-axis) from 24-week-old male Sox9-EGFP reporter mice 490 
(n=3). Only microRNAs with average RPMMM > 1000 are displayed. Each data point 491 
represents a microRNA, miR-375 is labeled. (c) Scatter plot showing average expression 492 
of microRNAs from small RNA-sequencing in Sox9-Low cells (y-axis) and fold-493 
enrichment in Sox9-Low cells relative to unsorted intestinal epithelial cells (x-axis) from 494 
24-week-old male Sox9-EGFP reporter mice (n=3). Only microRNAs with average 495 
RPMMM > 1000 are displayed. Each data point represents one single microRNA, miR-496 
375 is labeled. (d) Scatter plot showing average expression of microRNAs from small 497 
RNA-sequencing in Sox9-Sublow cells (y-axis) and fold-enrichment in Sox9-Sublow 498 
cells relative to unsorted intestinal epithelial cells (x-axis) from 24-week-old male Sox9-499 
EGFP reporter mice (n=3). Only microRNAs with average RPMMM > 1000 are 500 
displayed. Each data point represents a microRNA, miR-375 is labeled. (e) Scatter plot 501 
showing average expression of microRNAs from small RNA-sequencing in Sox9-Neg 502 
cells (y-axis) and fold-enrichment in Sox9-Neg cells relative to unsorted intestinal 503 
epithelial cells (x-axis) from 24-week-old male Sox9-EGFP reporter mice (n=3). Only 504 
microRNAs with average RPMMM > 1000 are displayed. Each data point represents a 505 
microRNA. 506 
 507 
Supplemental Figure Legends 508 
Supplemental Figure 1. Analysis of plasma levels of miR-375, GIP, and GLP-1, during 509 
an oral glucose tolerance test (OGTT), an intravenous isoglycemic glucose infusion 510 
(IIGI), and during the fasting control (Control). (a) Comparison of area under the curve 511 
16 
 
analyses for miR-375 during the OGTT, IIGI, and fasting control. (b) Comparison of area 512 
under the curve analyses for GIP during the OGTT, IIGI, and fasting control. (c) 513 
Comparison of area under the curve analyses for GLP-1 during the OGTT, IIGI, and 514 
fasting control. (d) Plasma levels of total GIP plotted against plasma levels of miR-375 515 
from each individual patient during the OGTT and IIGI. (e) Plasma levels of total GLP-1 516 
plotted against plasma levels of miR-375 from each individual patient during the OGTT 517 
and IIGI. The summary of statistical analyses for these datasets is compiled in 518 
Supplemental Table 1. 519 
 520 
Supplemental Figure 2. Quantification of miR-148a and miR-27b in the plasma of 521 
healthy human individuals during an oral glucose tolerance test (OGTT), an intravenous 522 
isoglycemic glucose infusion (IIGI), or during a 3-hour fasting control. (a) Plasma miR-523 
148a levels during the OGTT (open circles), the IIGI (filled squares), and the fasting 524 
control (open squares). (b) Plasma miR-27b levels during the OGTT (open circles), the 525 
IIGI (filled squares), and the fasting control (open squares). Results are presented as 526 
mean ± SEM.  527 
 528 
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